A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
Cell cycle checkpoints (G1/S, intra-S, G2/M, spindle checkpoints) monitor DNA integrity and proper mitotic progression. DNA damage activates sensor kinases (ATM, ATR) that stabilize p53, the 'guardian of the genome,' which halts the cell cycle, induces DNA repair, or triggers apoptosis if damage is irreparable. Loss of checkpoint control (via p53 mutations, Rb inactivation, or cyclin/CDK dysregulation) allows damaged DNA to replicate, driving genomic instability and cancer. Understanding checkpoint mechanisms is central to cancer biology and therapy.
From your study of cell cycle regulation, you know that cyclin-CDK complexes drive the cell through G1, S, G2, and M phases in an ordered sequence, and from DNA repair mechanisms, you know that cells have enzymatic systems to fix damaged DNA. Checkpoints are where these two systems meet — they are the surveillance mechanisms that halt the cell cycle when something goes wrong, buying time for repair or, if the damage is too severe, triggering cell death. Cancer arises when these checkpoints fail.
The G1/S checkpoint (also called the restriction point) is the cell's most consequential decision: commit to DNA replication or stop. The gatekeeper here is the retinoblastoma protein (Rb), which in its unphosphorylated state binds and silences the E2F transcription factors needed to express S-phase genes. Growth factor signaling drives cyclin D-CDK4/6 to partially phosphorylate Rb, then cyclin E-CDK2 completes the job, releasing E2F and committing the cell to S phase. If DNA damage is detected before this point, the sensor kinases ATM (responding to double-strand breaks) and ATR (responding to replication stress) activate Chk1 and Chk2, which phosphorylate and stabilize p53. Stabilized p53 induces transcription of p21, a CDK inhibitor that blocks cyclin E-CDK2, keeping Rb hypophosphorylated and E2F silenced. The cell arrests in G1, and repair enzymes go to work.
The G2/M checkpoint acts as a final quality check before mitosis. If DNA damage persists or replication errors occurred during S phase, the same ATM/ATR → Chk1/Chk2 pathway activates, this time targeting the phosphatase Cdc25, which is needed to activate cyclin B-CDK1 (the master trigger of mitotic entry). Chk1 phosphorylates Cdc25, marking it for degradation or cytoplasmic sequestration, so CDK1 stays inhibited and the cell cannot enter mitosis. The spindle assembly checkpoint operates during M phase itself: unattached kinetochores generate a "wait" signal via the mitotic checkpoint complex (MCC), which inhibits the anaphase-promoting complex (APC/C) until every chromosome is properly bi-oriented on the spindle. Only when all kinetochores are attached does the checkpoint silence, allowing APC/C to trigger sister chromatid separation.
The link to cancer becomes clear when you consider what happens if these checkpoints are disabled. p53 is mutated in over half of all human cancers — without it, cells with DNA damage sail through G1/S without arrest, accumulating mutations with each division. Rb loss removes the restriction point brake entirely. Overexpression of cyclins D or E, or loss of CDK inhibitors like p16 or p21, has the same effect: unrestrained proliferation despite genomic damage. This progressive accumulation of mutations — called genomic instability — is the hallmark of cancer progression. It explains why cancer typically requires multiple "hits" (Knudson's two-hit hypothesis): one checkpoint failure alone is often compensated by others, but sequential losses create a cell that divides relentlessly, ignores damage signals, and evades apoptosis. Modern cancer therapies increasingly target these pathways — CDK4/6 inhibitors (palbociclib) restore the G1 brake in Rb-positive tumors, while synthetic lethality strategies exploit checkpoint deficiencies to selectively kill cancer cells.